Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Roche's Tecentriq approved by -2-

05/05/2021 | 01:00am EDT
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
 
   *High programmed death ligand-1 (PD-L1) expression in the indication 
statement is defined as PD-L1 stained >=50% of tumour cells (TC) [TC 
>=50%] or PD-L1 stained tumour-infiltrating cells (IC) covering >=10% of 
the tumour area [IC >=10%]. PD-L1 staining is the process by which the 
PD-L1 protein is visualised during testing. 
 
   All trademarks used or mentioned in this release are protected by law. 
 
   References 
 
   [1] Herbst RS, et al. Atezolizumab for first-line treatment of 
PD-L1-selected patients with NSCLC. N Engl J Med 2020:383:1328--39. 
 
   [2] Supplement to: Herbst RS, et al. Atezolizumab for first-line 
treatment of PD-L1-selected patients with NSCLC. N Engl J Med 
2020;383:1328--39. 
 
   [3] Herbst RS, et al. IMpower110: updated OS analysis of atezolizumab vs 
platinum-based chemotherapy as first-line treatment in PD-L1--selected 
NSCLC [WCLC 2020 Poster FP13.03]. 
 
   [4] World Health Organization: GLOBOCAN 2020 -- Lung Cancer: Estimated 
cancer incidence, mortality and prevalence worldwide. [Internet; cited 
March 2021] Available from: 
https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. 
 
 
   [5] American Cancer Society: What Is Lung Cancer? [Internet; cited March 
2021]: Available from: 
https://www.cancer.org/cancer/lung-cancer/about/what-is.html. 
 
   Roche Group Media Relations 
 
   Phone: +41 61 688 8888 / e-mail: media.relations@roche.com 
https://www.globenewswire.com/Tracker?data=TYXKox3bKJCZBhvgCo3ueQFwVW9fee4r4W3daOf0o6X7m94Vyk4TRogEJ1027o2XxScUq9jTp-H-dw5SqboKJKdO7bVLhc_VSzyvNgso5iTWjsROPvCmbXz_cWG9fhW9 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
 
 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                        Jon Kaspar Bayard 
 Phone: +41 61 68-78503                 Phone: +41 61 68-83894 
 e-mail: karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
Dr. Sabine Borngräber             Dr. Bruno Eschli 
 Phone: +41 61 68-88027                 Phone: +41 61 68-75284 
 e-mail: sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
Dr. Birgit Masjost                     Dr. Gerard Tobin 
 Phone: +41 61 68-84814                 Phone: +41 61 68-72942 
 e-mail: birgit.masjost@roche.com       e-mail: gerard.tobin@roche.com 
 
Investor Relations North America 
Loren Kalm                             Dr. Lisa Tuomi 
 Phone: +1 650 225 3217                 Phone: +1 650 467 8737 
 e-mail: kalm.loren@gene.com            e-mail: tuomi.lisa@gene.com 
 
 
 
 
   Attachment 
 
 
   -- 05052021_MR_IMpower110 EMA approval _en 
      https://ml-eu.globenewswire.com/Resource/Download/519d499c-58c1-49da-9504-2d688a19d974 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 05, 2021 01:00 ET (05:00 GMT)

All news about ROCHE HOLDING AG
05/06Switzerland says U.S. stance on vaccine patent waiver leaves questions
RE
05/06Switzerland says U.S. announcement on vaccine patent waiver leaves questions
RE
05/06Indian shares pare gains as coronavirus cases surge past 21 mln
RE
05/05ROCHE  : Antibody Cocktail Lands Emergency Use Authorization in India
MT
05/05German pharma firm Cheplapharm considers options including IPO
RE
05/05ROCHE  : Secures EU Nod For Tecentriq in Metastatic Non-Small Cell Lung Cancer P..
MT
05/05PRESS RELEASE  : Roche's Tecentriq approved by -2-
DJ
05/05PRESS RELEASE  : Roche's Tecentriq approved by European Commission as a first-li..
DJ
05/05ROCHE  : Tecentriq approved by European Commission as a first-line monotherapy t..
AQ
05/04ROCHE  : MEDIA-EU eyes joint purchase of COVID treatments in long virus fight- B..
RE
More news
Financials
Sales 2021 60 430 M 67 084 M 67 084 M
Net income 2021 14 600 M 16 207 M 16 207 M
Net cash 2021 4 301 M 4 774 M 4 774 M
P/E ratio 2021 18,0x
Yield 2021 3,10%
Capitalization 262 B 290 B 290 B
EV / Sales 2021 4,26x
EV / Sales 2022 4,06x
Nbr of Employees 101 465
Free-Float 82,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 354,31 CHF
Last Close Price 303,20 CHF
Spread / Highest target 44,5%
Spread / Average Target 16,9%
Spread / Lowest Target -4,35%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-1.88%289 958
JOHNSON & JOHNSON7.07%443 727
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539
NOVARTIS AG-4.97%197 775